{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-161596","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2023-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.708874+00:00","generated_at":"2026-06-14T06:39:02.566332+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cogent Biosciences reports positive Phase 3 PEAK lead-in data for bezuclastinib in GIST","bullets":["39 patients treated; 55% disease control rate across efficacy-evaluable patients in Part 1.","In 2nd-line Part 1a: 100% disease control rate and 17% overall response rate.","Safety profile well-tolerated; 2 discontinuations due to AEs; low Grade ≥3 events.","Part 2 enrollment ongoing (target ~388 2nd-line GIST patients); SUMMIT/APEX data expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-161596","json":"https://secwatch.observer/filing/0001193125-23-161596.json","markdown":"https://secwatch.observer/filing/0001193125-23-161596.md","text":"https://secwatch.observer/filing/0001193125-23-161596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312523161596/0001193125-23-161596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312523161596/d425875d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T06:39:02.566332+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}